论文部分内容阅读
我国肺癌患者占男性常见肿瘤的第1位,女性的第2位。其中80%为非小细胞肺癌,采用何种方法能够早期诊断肺癌,并对患者的治疗进行预测,对癌前病变进行干预,是一项紧迫而有意义的工作。我院肺癌患者于治疗前后均行肿瘤异常蛋白(TAP)检测,据治疗前后的检查,结合TAP检测结果判定疗效,据自身对照分析明确TAP检测是否可以作为肺癌的疗效检测指标,报告如下。1资料与方法1.1临床资料:2009年1月至2012年2月在河北省胸科医院入院治疗的肺癌患者268例,有免疫缺陷者除外,年
Lung cancer patients in China accounted for the first common male tumors, women’s second place. 80% of them are non-small cell lung cancer. It is an urgent and meaningful task to use early diagnosis methods to diagnose lung cancer and predict the treatment of the patients. Tumor necrosis factor (TAP) test was performed before and after treatment in patients with lung cancer in our hospital. According to the examination before and after the treatment, combined with the TAP test results to determine the efficacy, according to their own control analysis to determine whether TAP can be used as lung cancer curative effect detection indicators are as follows. 1 Materials and Methods 1.1 Clinical data: 268 cases of lung cancer patients admitted to Hebei Chest Hospital from January 2009 to February 2012, with the exception of immunodeficiency, the year